Close Menu

GeneCentric Diagnostics

GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.

The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.

The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.